Diceros Therapeutics, Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2022 | $13 M | No. 1 | $10 to $50 million | equity, options | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Diceros Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2024).
SEC Form D · Aug 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2024
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Diceros Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Stephen R. Seiler | Executive officer | Aug 2024 |
| Ids R. van der Weij | Director | Aug 2024 |
| Jonathan R. Fleming | Director | Aug 2024 |
| Stephen R. Seiler | Director | Aug 2024 |
| Wyatt R. Gotbetter | Director | Aug 2024 |